Quantum Genomics Société Anonyme
Quantum Genomics Société Anonyme, a healthtech company, develops of drugs to treat cardiovascular diseases. Quantum Genomics Société Anonyme was incorporated in 2005 and is headquartered in Paris, France.
Quantum Genomics Société Anonyme (QNNTF) - Total Assets
Latest total assets as of December 2024: $354.65K USD
Based on the latest financial reports, Quantum Genomics Société Anonyme (QNNTF) holds total assets worth $354.65K USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Quantum Genomics Société Anonyme - Total Assets Trend (2012–2024)
This chart illustrates how Quantum Genomics Société Anonyme’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Quantum Genomics Société Anonyme - Asset Composition Analysis
Current Asset Composition (December 2024)
Quantum Genomics Société Anonyme's total assets of $354.65K consist of 99.6% current assets and 0.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Quantum Genomics Société Anonyme's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Quantum Genomics Société Anonyme's current assets represent 99.6% of total assets in 2024, an increase from 71.1% in 2012.
- Cash Position: Cash and equivalents constituted 84.9% of total assets in 2024, up from 4.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 6.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Quantum Genomics Société Anonyme Competitors by Total Assets
Key competitors of Quantum Genomics Société Anonyme based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Quantum Genomics Société Anonyme - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Quantum Genomics Société Anonyme generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Quantum Genomics Société Anonyme is currently not profitable relative to its asset base.
Quantum Genomics Société Anonyme - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.05 | 2.73 | 3.35 |
| Quick Ratio | 2.05 | 2.82 | 3.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $181.15K | $ 2.34 Million | $ 9.98 Million |
Quantum Genomics Société Anonyme - Advanced Valuation Insights
This section examines the relationship between Quantum Genomics Société Anonyme's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.88 |
| Latest Market Cap to Assets Ratio | 17.89 |
| Asset Growth Rate (YoY) | -90.5% |
| Total Assets | $354.65K |
| Market Capitalization | $6.34 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Quantum Genomics Société Anonyme's assets at a significant premium ( 17.89x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Quantum Genomics Société Anonyme's assets decreased by 90.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Quantum Genomics Société Anonyme (2012–2024)
The table below shows the annual total assets of Quantum Genomics Société Anonyme from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $354.65K | -90.53% |
| 2023-12-31 | $3.75 Million | -84.16% |
| 2022-12-31 | $23.66 Million | +11.37% |
| 2021-12-31 | $21.24 Million | -35.24% |
| 2020-12-31 | $32.80 Million | +121.95% |
| 2019-12-31 | $14.78 Million | -20.03% |
| 2018-12-31 | $18.48 Million | +32.79% |
| 2017-12-31 | $13.92 Million | -4.08% |
| 2016-12-31 | $14.51 Million | +37.65% |
| 2015-12-31 | $10.54 Million | +121.78% |
| 2014-12-31 | $4.75 Million | +180.76% |
| 2013-12-31 | $1.69 Million | +60.21% |
| 2012-12-31 | $1.06 Million | -- |